Invest on your own
Build your own portfolio, stock by stock.
We do it for you
Professionally managed portfolios, built and rebalanced for you.
NEW
How we screen every stock
Our halal screening & purification process in 3 minutes
Screeners
Your portfolio
Calculators
TOOL
Check any stock in seconds
Search 11,000+ tickers and see the halal verdict instantly.
Our certifications
Independent proof that every stock and portfolio meets halal standards.
METHODOLOGY
How we screen every stock
Our 5-step halal methodology, in 90 seconds.
Get help
NEW
Halal investing 101
A beginner-friendly intro to investing the halal way.
Plans by product
COMPARE
Find your plan
See every feature side-by-side and pick what fits.
Investors
INVESTORS
Invest in Musaffa
We're building the financial house for 1.9B Muslims. See the deck.
RCUS Shariah Compliance
Screening Methodology: AAOIFI
NOT HALAL
Last Updated: May 08, 2026
Report Source: 2026 1st Quarter Report
Arcus Biosciences Inc. Stock Analysis RCUS
United States Health Care Mid Cap Report: Arcus Biosciences, Inc. is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of immunotherapies. The company is headquartered in Hayward, California and currently employs 601 full-time employees. The company went IPO on 2018-03-15. The firm has a portfolio of investigational products, which are in clinical development with its advanced molecule, an anti-TIGIT antibody targeting lung and gastrointestinal cancers. The firm has approximately seven clinical programs that are focused on targets, including TIGIT, PD-1, adenosine A2a and A2b receptors, CD73, CD39, HIF-2a, and AXL. The firm is engaged in co-developing four investigational products, including zimberelimab (Arcuss anti-PD-1 molecule), domvanalimab (Arcuss anti-TIGIT antibody), etrumadenant (Arcuss adenosine receptor antagonist) and quemliclustat (Arcuss CD73 inhibitor). The company is engaged in pursuing a Phase II and Phase III development program for domvanalimab in combination with its anti-PD-1 antibody, zimberelimab, in multiple settings, including lung and gastrointestinal cancer.
Read More Arcus Biosciences Inc (RCUS) Chart
Key Statistics of Arcus Biosciences Inc (RCUS)
Key statistics in the stock market are essential financial indicators that measure a company's performance, valuation, profitability, and risk.
Today's Range
Today's Open
$26.72Volume
2.34MP/E Ratio (TTM)
-52 Week Range
Market Cap
3.00BAvg. Volume
1.38MDividend Yield
-Financial Metrics & Statements of Arcus Biosciences Inc (RCUS)
FAQ's for Arcus Biosciences Inc (RCUS)
- According to Musaffa’s Shariah screening methodology, Arcus Biosciences Inc (RCUS) is currently classified as NOT HALAL as of May 2026. The classification is based on an evaluation of the company’s business activities and financial ratios to determine whether it meets Islamic investment guidelines.
- A stock is Shariah-compliant if the company operates in permissible business activities and meets Islamic financial screening thresholds. Musaffa analyzes Arcus Biosciences Inc using these criteria to determine its compliance status.
- Muslim investors may consider investing in Arcus Biosciences Inc if it meets Shariah compliance standards. Investors typically review the company’s business activities, debt levels, and non-permissible income before making a decision.
- Musaffa determines the Shariah status of Arcus Biosciences Inc by analyzing whether the company’s core business operations are permissible and whether its financial ratios fall within accepted Islamic thresholds.
- The Shariah compliance status of Arcus Biosciences Inc may be updated periodically when new financial statements, earnings reports, or business activity information become available.
- Yes. A stock that is currently Shariah-compliant may become non-compliant if the company’s financial ratios exceed Shariah thresholds or its business activities change.
- You can check the latest Shariah compliance status of Arcus Biosciences Inc on Musaffa’s stock page, where screening results and key financial indicators are updated to help Muslim investors make informed decisions.